scholarly journals Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis

2011 ◽  
Vol 3 (2) ◽  
pp. 89 ◽  
Author(s):  
Sue-Jung Jee ◽  
Joo-Hwa Kim ◽  
Hey-Sung Baek ◽  
Ha-Baik Lee ◽  
Jae-Won Oh
Keyword(s):  
Atopic Dermatitis ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy ◽  
Term Efficacy

Efficacy of Intravenous Immunoglobulin Therapy in Childhood Atopic Dermatitis

2012 ◽  
Vol 18 (1) ◽  
pp. 26-31
Author(s):  
Eun Kyeong Yeon ◽  
A Young Park ◽  
Sanghoon Chae ◽  
Seung Soo Kim ◽  
Kyeong Bae Park ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy

Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders

2017 ◽  
Vol 56 (6) ◽  
pp. 1173-1176 ◽  
Author(s):  
Aidan A. Levine ◽  
Todd D. Levine ◽  
Kathie Clarke ◽  
David Saperstein
Keyword(s):  
Side Effects ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy ◽  
Neurologic Disorders

scholarly journals Transient Hypogammaglobulinemia and Severe Atopic Dermatitis: Open-label Treatment with Immunoglobulin in a Case Series

2016 ◽  
Vol 7 (2) ◽  
pp. ar.2016.7.0164 ◽  
Author(s):  
Moira E. Breslin ◽  
Joanna H. Lin ◽  
Robert Roberts ◽  
Kellie J. Lim ◽  
E. Richard Stiehm
Keyword(s):  
Atopic Dermatitis ◽  
Los Angeles ◽  
Intravenous Immunoglobulin ◽  
Conventional Therapy ◽  
Case Series ◽  
Retrospective Chart Review ◽  
Immunoglobulin Therapy ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Intravenous Immunoglobulin Therapy

Background We reported on six infants between 5 and 11 months old, with transient hypogammaglobulinemia of infancy and severe refractory atopic dermatitis, who were treated with open-label immunoglobulin (Ig) after conventional therapy failed. All six infants had an IgG level of <225 mg/dL, elevated eosinophil and IgE levels, and no urine or stool protein losses, but they did exhibit hypoalbuminemia. Objective To evaluate the utility of open-label immunoglobulin in infants with severe atopic dermatitis for whom conventional therapy failed. We reviewed the clinical utility of intravenous immunoglobulin in the treatment of severe atopic dermatitis, the most recent research in the field, and suggested mechanisms for its benefit. Methods The six infants were identified from a retrospective chart review at the University of California Los Angeles Allergy and Immunology outpatient pediatric clinic. Results All six patients were treated with 400 mg/kg/month of intravenous immunoglobulin and had normalization of their IgG and albumin levels, and all but one had clinically improved atopic dermatitis. Conclusion Infants with severe atopic dermatitis who did not respond to conventional therapy avoidance may benefit from intravenous immunoglobulin therapy.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy - An Overview of Intravenous Immunoglobulin Therapy

2009 ◽  
Vol 4 (1) ◽  
pp. 72
Author(s):  
Vera Bril ◽  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Ivig Therapy ◽  
Immunoglobulin Therapy ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Intravenous Immunoglobulin Therapy ◽  
Short And Long Term ◽  
Term Data ◽  
Ivig Administration

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a significant source of disability, and early diagnosis and immunomodulatory therapy administration are critical to minimise disease progression and axonal degeneration. Intravenous immunoglobulin (IVIg) therapy is considered to be a first-line treatment for CIDP. Comparative short- and long-term data of IVIg versus corticosteroids in CIDP patients are limited. Of the five published placebo-controlled studies in CIDP, four reported only on short-term improvements in disability (≤6 weeks). However, the IGIV CIDP Efficacy (ICE) study, the largest randomised, placebo-controlled CIDP study published to date (n=117), reported significant improvements in disability, functional impairment and quality of life with IVIg (Gamunex®) 1g/kg maintenance therapy every three weeks for up to 48 weeks. Furthermore, long-term IVIg administration was safe and well tolerated, particularly given the short duration of the infusions. Data suggest that a long-term scheduled maintenance regimen of IVIg in appropriate patients may provide substantial benefit and reduce the risk of CIDP relapse.

Different responses of human anti-HLA and anti-αgal antibody to long-term intravenous immunoglobulin therapy

1999 ◽  
Vol 6 (3) ◽  
pp. 181-186 ◽  
Author(s):  
L. Bühler ◽  
D. Pidwell ◽  
R.D. Dowling ◽  
D. Newman ◽  
M. Awwad ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy
Sign in / Sign up

Export Citation Format

Share Document